Ablynx, Taisho PartnerBy
Ablynx, a biopharmaceutical company, has formed an exclusive license agreement with Taisho Pharmaceutical Co., Ltd. for the development and commercialization of Ablynx's anti-TNFÎ± Nanobody, ozoralizumab, in Japan, for the treatment of rheumatoid arthritis (RA).
Under the agreement, Taisho will be responsible for development, registration, and commercialization of anti-TNFÎ± Nanobody therapeutics in Japan. Ablynx will receive an upfront payment of $3 million and is entitled to receive development and commercial milestone payments plus royalties based on annual net sales of anti-TNFÎ± Nanobody therapeutics generated in Japan.
Ozoralizumab is a TNFÎ± blocker with clinical Phase II proof-of-concept in RA. The therapeutic molecule consists of two Nanobodies targeting TNFÎ±, which are linked to a Nanobody that binds to human serum albumin, extending the drug's half-life and improving its distribution to inflamed oints in vivo. In September 2014, Ablynx granted an exclusive royalty-bearing license to Eddingpharm, a Chinese specialty pharmaceutical companies, to develop and commercialize ozoralizumab in Greater China.